A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice

Peptides

Volumn 27, Issue 5, 2006, Pages 964-972

  Marchand, Stéphane ^a   Betourne, Alexandre ^a   Marty, Virginie ^a   Daumas, Stéphanie ^a   Halley, Hélène ^a   Lassalle, Jean Michel ^a   Zajac, Jean Marie ^b   Frances, Bernard ^a  

^a CNRS   (France)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Conditioned place preference; Ethanol; Morphine; Mouse; Neuropeptide FF; Reward

Indexed keywords

ALCOHOL; MORPHINE; NEUROPEPTIDE FF;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MOUSE; MOUSE STRAIN; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT; REWARD;

ANIMALS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); ETHANOL; FEMALE; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, INBRED C57BL; MORPHINE; OLIGOPEPTIDES; RECEPTORS, NEUROPEPTIDE; REWARD;

ANIMALIA;

EID: 33646151645     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.07.023     Document Type: Article

References (48)

1. Altier N., and Stewart S. Neuropeptide FF in the VTA blocks the analgesic affect of both intra-VTA morphine and exposure to stress. Brain Res 758 (1997) 250-254
2. Ballet S., Braz J., Mauborgne A., Bourgoin S., Zajac J.M., Hamon M., et al. The neuropeptide FF analogue, 1DMe, reduces in vivo dynorphin release from the rat spinal cord. J Neurochem 81 (2002) 659-662
3. Ballet S., Mauborgne A., Gouarderes C., Bourgoin S., Zajac J.M., Hamon M., et al. The neuropeptide FF analogue, 1DMe, enhances in vivo met-enkephalin release from the rat spinal cord. Neuropharmacology 38 (1999) 1317-1324
4. Bardo M.T., and Brevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology 153 (2000) 31-43
5. Bonini J.A., Jones K.A., Adham N., Forray C., Artymyshyn R., Durkin M.M., et al. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem 275 (2000) 39324-39331
6. Cador M., Marco N., Stinus L., and Simonnet G. Interaction between neuropeptide FF and opioids in the ventral tegmental area in the behavioral response to novelty. Neuroscience 110 (2002) 309-318
7. Chen J.C., Li J.Y., Liang K.W., and Huang Y.K. neuropeptide FF potentiates the behavioural sensitization to amphetamine and alters the levels of neurotransmitters in the medial prefrontal cortex. Brain Res 816 (1999) 220-224
8. Ciccocioppo R., Angeletti S., Panocka I., and Massi M. Nociceptin/orphanin FQ and drugs of abuse. Peptides 21 (2000) 1071-1080
9. Ciccocioppo R., Angeletti S., Sanna P.P., Weiss F., and Massi M. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol 404 (2000) 153-159
10. Ciccocioppo R., Economidou D., Fedeli A., Angeletti S., Weiss F., Heilig M., et al. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology 172 (2004) 170-178
11. Cowen M.S., and Lawrence A.J. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Behav 23 (1999) 1171-1212
12. Crespi F., Corsi M., England T., Ratti E., Trist D.G., and Gaviraghi G. Spontaneous preference for ethanol in naive rats is influenced by cholecystokinin A receptor antagonism. Alcohol 14 (1997) 327-332
13. Devine D.P., Reinscheid R.K., Monsma Jr. F.J., Civelli O., and Akil H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 727 (1996) 225-229
14. Funada M., Suzuki T., Narita M., Misawa M., and Nagase H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 32 (1993) 1315-1323
15. Gelot A., Frances B., Gicquel S., and Zajac J.M. Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. Eur J Pharmacol 358 (1998) 203-206
16. Gelot A., Frances B., Roussin A., Latapie J.P., and Zajac J.M. Anti-opioid efficacy of neuropeptide FF in morphine-tolerant mice. Brain Res 808 (1998) 166-173
17. Gicquel S., Mazarguil H., Allard M., Simonnet G., and Zajac J.M. Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects. Eur J Pharmacol 222 (1992) 61-67
18. Gouardères C., Jhamandas K., Sutak M., and Zajac J.M. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues. Brit J Pharmacol 117 (1996) 493-501
19. Gouardères C., Puget A., and Zajac J.M. Detailed distribution of neuropeptide FF receptors (NPFF1 and NPFF2) in the rat, mouse, octodon, rabbit, guinea pig and marmoset monkey brains: a comparative autoradiographic study. Synapse 51 (2004) 249-269
20. Hall F.S., Sora I., and Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology 154 (2001) 43-49
21. Higgins G.A., Nguyen P., and Sellers E.M. Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists. Brain Res 572 (1992) 208-215
22. Hinuma S., Shintani Y., Fukusumi S., Iijima N., Matsumoto Y., Hosoya M., et al. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol 2 (2000) 703-708
23. Huang E.Y., Li J.Y., Wong C.H., Tan P.P., and Chen J.C. Dansyl-PQRamide, a possible neuropeptide FF receptor antagonist, induces conditioned place preference. Peptides 23 (2002) 489-496
24. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
25. Kotani M., Mollereau C., Detheux M., Le Poul E., Brezillon S., Vakili J., et al. Functional characterization of a human receptor for neuropeptide FF and related peptides. Brit J Pharmacol 133 (2001) 138-141
26. Kuzmin A., Sandin J., Terenius L., and Ögren S.O. Acquisition, expression and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J Pharmacol Exp Ther 304 (2003) 310-318
27. Lake J.R., Hammond M.V., Shaddox R.C., Hunsicker L.M., Yang H.Y.T., and Malin D.H. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett 132 (1991) 29-32
28. Lake J.R., Hebert K.M., Payza K., Deshotel K.D., Hausam D.D., Witherspoon W.E., et al. Analogs of neuropeptide FF attenuate morphine tolerance. Neurosci Lett 146 (1992) 203-206
29. Larsson A., and Engel J.A. Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci Biobehav Rev 27 (2004) 713-720
30. Little H.J., Butterworth A.R., O Callaghan M.J., Wilson J., Cole J., and Watson W.P. Low alcohol preference among the "high alcohol preference" C57 strain of mice; preference increased with saline injections. Psychopharmacology 147 (1999) 182-189
31. 2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 11 (1990) 277-280
32. Manzanedo C., Serrano A., Aguilar M.A., Rodriguez-Arias M., and Minarro J. Effects of CGS 10746B on hyperactivity and place preference induced by morphine. Behav Brain Res 126 (2001) 23-32
33. Marco N., Stinus L., Allard M., Le Moal M., and Simonnet G. Neuropeptide FLFQRFamide receptors within the ventral mesencephalon and dopaminergic terminal areas: localization and functional anti-opioid involvement. Neuroscience 64 (1995) 1035-1044
34. Mazarguil H., Gouarderes C., Tafani J.A., Marcus D., Kotani M., Mollereau C., et al. Structure-activity relationships of neuropeptide FF: role of C-terminal regions. Peptides 22 (2001) 1471-1478
35. Mollereau C., Gouarderes C., Dumont Y., Kotani M., Detheux M., Doods H., et al. Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226. Brit J Pharmacol 133 (2001) 1-4
36. Murphy N.P., Lam H.A., and Maidment N.T. A comparison of morphine-induced locomotor activity and mesolimbic dopamine release in C57BL/6, 129SV and DBA2 mice. J Neurochem 79 (2001) 626-635
37. Murphy N.P., Lee Y., and Maidment N.T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 832 (1999) 168-170
38. Narita M., Kishimoto Y., Ise Y., Misawa K., and Suzuki T. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 30 (2005) 111-118
39. Ng G.Y., O'Dowd B.F., and George S.R. Genotypic differences in mesolimbic enkephalin gene expression in DBA/2J and C57BL/6J inbred mice. Eur J Pharmacol 311 (1996) 45-52
40. Perry S.J., Huang E.Y., Cronk D., Bagust J., Sharma R., Walker R.J., et al. A human gene coding morphine modulating peptides related to NPFF and FMRFamide. FEBS Lett 409 (1997) 426-430
41. Quelven I., Roussin A., Burlet-Schiltz O., Gouarderes C., Tafani J.A., Mazarguil H., et al. Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs. Eur J Pharmacol 449 (2002) 91-98
42. Quelven I., Roussin A., and Zajac J.M. Functional consequences of neuropeptide FF receptors stimulation in mouse: a cerebral glucose uptake study. Neuroscience 126 (2004) 441-449
43. Roumy M., and Zajac J.M. Neuropeptide FF: pain and analgesia. Eur J Pharmacol 345 (1998) 1-11
44. Singh L., Field M.J., Hunter J.C., Oles R.J., and Woodruff G.N. Modulation of the in vivo actions of morphine by the mixed CCKA/B receptor antagonist PD142898. Eur J Pharmacol 307 (1996) 283-289
45. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56 (1998) 613-672
46. Vilim F.S., Aarnisalo A.A., Nieminen M.L., Lintunen M., Karlstedt K., Kontinen V.K., et al. Gene for pain modulatory neuropeptide NPFF: induction in spinal cord by noxious stimuli. Mol Pharmacol 55 (1999) 804-811
47. Yang H.Y.T., Fratta W., Majane E.A., and Costa E. Isolation, sequencing, analysis, synthesis, and pharmacological characterization of the two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci (USA) 82 (1985) 7757-7761
48. Zajac J.M. Neuropeptide FF: new molecular insights. Trends Pharmacol Sci 22 (2001) 63